Zimeldine (Zimelidine)

One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)

Also Known As:

Networked: 115 relevant articles (7 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Levkovitz, Yeciel: 1 article (04/2011)
2.	Papakostas, George I: 1 article (04/2011)
3.	Tedeschini, Enrico: 1 article (04/2011)
4.	Brochu, Richard M: 1 article (04/2007)
5.	Priest, Birgit T: 1 article (04/2007)
6.	Purohit, Yamini: 1 article (04/2007)
7.	Dick, Ivy E: 1 article (04/2007)
8.	Martin, William J: 1 article (04/2007)
9.	Kaczorowski, Gregory J: 1 article (04/2007)
10.	Strac, D S: 1 article (12/2006)

Related Diseases

1.	Pain (Aches) 04/01/1986 - "Twenty patients with chronic pain of non-malignant origin (mean duration 15.8 years) were entered into a double blind cross-over study of the analgesic efficacy of zimelidine and placebo. " 12/01/1979 - "Visual evoked potentials as a predictor of reported side effects during a trial of zimelidine vs. placebo in chronic pain patients." 08/01/1979 - "A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients." 04/01/1986 - "Zimelidine was superior (P less than 0.05) to placebo with respect to pain relief based on a global assessment (by the clinical investigators) performed at the completion of each treatment phase. " 01/01/1980 - "The results also indicate that treatment with Zimelidine may result in a decreased sensitivity to noxious stimulation that should be reflected in relief of clinical pain syndromes."
2.	Depressive Disorder (Melancholia) 05/01/1986 - "The present results suggest that zimelidine may be more effective in the treatment of severely depressed patients, rather than those with more mild mixed anxiety/depressive syndromes." 01/01/1982 - "An open trial of zimelidine in patients with endogenous depression." 01/01/1984 - "Thirty-nine (39) patients entered a double blind study conducted to compare the therapeutic efficacy and safety of Zimelidine and amitriptyline in endogenous depression. " 01/01/1984 - "Double blind study comparing the efficacy of zimelidine and amitriptyline in endogenous depression." 01/01/1983 - "The aim of this study was to evaluate the safety of zimeldine, a 5-HT reuptake inhibitor, in the long-term treatment of depressive disorders. "
3.	Major Depressive Disorder (Major Depressive Disorders) 01/01/1983 - "The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders was evaluated in a randomized, placebo-controlled study involving 40 patients. " 01/01/1983 - "The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders--a double-blind placebo-controlled study." 02/01/1983 - "Twenty-eight hospital inpatients with a primary major depressive disorder were treated with either zimelidine or placebo. " 01/01/1983 - "A multicentre double-blind comparative trial of zimeldine and imipramine in primary major depressive disorders." 01/01/1982 - "A double-blind, randomized clinical study was conducted in thirty-four out-patients suffering from major depressive disorders comparing zimelidine with amitriptyline. "
4.	Alcoholism (Alcohol Abuse) 09/01/1995 - "Studies of zimeldine, nialamide, L-dopa, viloxazine, and tetrabamate failed to demonstrate efficacy for these agents in the treatment of alcoholism. "
5.	Cataplexy 01/01/1986 - "Zimelidine, however, has no anticholinergic effect, so it is unlikely that cholinergic mechanisms thought to be important in animal cataplexy would play a major role in human cataplexy. " 01/01/1986 - "The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients." 12/01/1993 - "This, however, is an apparent contradiction to data obtained in human patients, which show that chronic oral administration of serotonergic uptake inhibitors, such as clomipramine, zimelidine and fluoxetine, is effective in reducing cataplexy. "

Related Drugs and Biologics

1.	Amitriptyline (Elavil)
2.	Viloxazine
3.	Nialamide
4.	Levodopa (L Dopa)
5.	tetrabamate
6.	Fluoxetine (Prozac)
7.	Clomipramine (Anafranil)
8.	Hydroxyindoleacetic Acid
9.	Endorphins
10.	Serotonin (5 Hydroxytryptamine)

Related Therapies and Procedures

1.	Oral Administration
2.	Analgesia